Results 71 to 80 of about 4,313 (158)

Effect of benralizumab treatment on the airway microbiome in COPD

ERJ Open Research
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil ...
Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R. Barer, Christopher McCrae, Christopher E. Brightling   +7 more
doaj   +1 more source

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj  

Benralizumab Depletes IL‐5Rα‐Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis

Clinical and Translational Allergy
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.
Christiane E. Whetstone, Ruth P. Cusack, Emma L. Price, Karen J. Howie, Caitlin Stevens, Dhuha Al‐Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman, Vanessa Luk, Paul M. O'Byrne, Mark D. Inman, Roma Sehmi, Hermenio Lima, Gail M. Gauvreau   +15 more
doaj   +1 more source

Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review

Respirology Case Reports
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disorder characterized by necrotizing vasculitis, asthma, and eosinophilia. We report a case of EGPA that developed during benralizumab treatment for severe asthma and provide a ...
Mitsukuni Sakabe, Kazunori Tobino, Yumi Obata, Shota Sogabe, Kazuki Uchida, Yosuke Murakami   +5 more
doaj   +1 more source

Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE

ERJ Open Research
Background In Europe, although multiple biologics have been approved for the treatment of severe asthma (SA), comparative data from real-world settings remain limited. This study compared the real-world effectiveness of dupilumab with that of omalizumab,
Giorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, Juby Jacob-Nara, Kinga Borsos, Richard H. Stanford, Zhixiao Wang, Mena Soliman, Lynn Huynh, Fariha Haque, Mei Sheng Duh, Wei-Han Cheng   +11 more
doaj   +1 more source

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab

ACR Open Rheumatology
Objective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler, Nancy Agmon‐Levin, David R. W. Jayne, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Sofia Necander, Anat Shavit, Claire Walton, Peter A. Merkel   +9 more
doaj   +1 more source

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Journal of Asthma and Allergy
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich ...
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K   +9 more
doaj  

Real-World Comparative Effectiveness of Mepolizumab versus Benralizumab in an Older Population with Asthma: A US Medicare Fee-for-Service Analysis. [PDF]

J Asthma Allergy
Germain G, Burrows E, Klimek J, Gravelle P, Tavakoli Tafti K, Laliberté F, Deb A.   +6 more
europepmc   +1 more source

Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms. [PDF]

J Inflamm Res
Maglio A, Vitale C, D'Auria LO, Longobardi V, Franzese A, Pelaia C, Pelaia G, Calabrese C, Vatrella A.   +8 more
europepmc   +1 more source

Prioritizing efficacy over convenience. [PDF]

Am J Respir Crit Care Med
Siddiqui S, Brooks L, Menzies-Gow A, Akuthota P.   +3 more
europepmc   +1 more source